trial

A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia

NCTId NCT03697252
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 182 (actual)
Sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Primary completion 2019-09-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
182 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2018-09-18
Primary completion
2019-09-04
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Xanomeline-trospium (Cobenfy)

Sponsors

Karuna Therapeutics, Inc., a Bristol Myers Squibb companyLead Sponsor

Investigators

1
Stephen Brannan, MDStudy Director

Sites

12 total
Little Rock, United StatesLemon Grove, United StatesLong Beach, United StatesOrange, United StatesSan Diego, United StatesAtlanta, United StatesGaithersburg, United StatesBerlin, United StatesDayton, United StatesAustin, United StatesDeSoto, United StatesRichardson, United States

Linked catalysts

1
A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophre — primary completion2019-09-04

Facts & assertions

4 sourced
Enrollment
182
Phase
PHASE2
Primary Completion Date
2019-09-04
Status
COMPLETED
relationships
The graph out of here
drug
Xanomeline-trospium (Cobenfy)
drug
lead_sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Stephen Brannan, MD
person